Business Context and Reporting Period
This Form 8-K Current Report was filed by Precision Optics Corporation, Inc. (POCI) on March 15, 2025, with the earliest event reported on that same date. The filing details significant changes to the Company's Board of Directors and executive compensation arrangements effective in March 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and personnel compensation.
Material Changes
Board of Directors Changes
- Resignation: Peter Anania resigned from the Board of Directors effective March 15, 2025.
- Appointment: Joseph P. Pellegrino, Jr. was appointed to the Board on March 19, 2025, to fill the vacancy. He was also appointed Chair of the Audit Committee.
- Committee Assignments: Buell Duncan was appointed to the Compensation Committee.
Executive and Director Compensation
- CEO Salary Increase: Joseph Forkey's annual base salary increased from $250,000 to $325,000, effective March 20, 2025.
- CEO Equity Grants: Mr. Forkey received a fully vested option for 80,000 shares, a three-year vesting option for 120,000 shares, and a fully vested stock grant of 20,000 shares.
- CFO and COO Equity Grants: Wayne Coll (CFO) received an option for 50,000 shares (two-year vesting), and Mahesh Lawande (COO) received an option for 40,000 shares (two-year vesting).
- Director Equity Grants: Mr. Pellegrino and Mr. Duncan each received a fully vested option for 30,000 shares and a two-year vesting option for 15,000 shares. Mr. Miclot received a two-year vesting option for 5,000 shares.
- Exercise Price: All stock options granted in this filing have an exercise price of $4.71 per share.
Compensation Policy Update
The Board updated the Non-Employee Director Compensation Policy to include annual cash awards of $20,000 for directors, with additional amounts for Committee Members ($5,000), Committee Chairs ($5,000), and the Chairman of the Board ($10,000). Annual stock option grants of 30,000 shares with quarterly vesting were also established.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, or specific risk factors. The primary contingency noted is that unvested shares granted to executives will vest immediately prior to a Change in Control.
Investor Verification Checklist
- Verify the impact of the new Board composition on strategic direction, particularly with the appointment of a former medical device CFO as Audit Chair.
- Review the dilution impact of the total equity grants (approximately 380,000 shares in options and 20,000 in stock) relative to the current share count.
- Confirm the updated Non-Employee Director Compensation Policy details in the Company's proxy statement or subsequent filings.
- Monitor the press release filed as Exhibit 99.1 for additional context on the leadership transition.